To test the role of telomere biology in T-cell prolymphocytic leukemia (T-PLL), a rare aggressive disease characterized by the expansion of a T-cell clone derived from immuno-competent post-thymic T-lymphocytes, we analyzed telomere length and telomerase activity in subsets of peripheral blood leukocytes from 11 newly diagnosed or relapsed patients with sporadic T-PLL. Telomere length values of the leukemic T cells (mean7s.d.: 1.5370.65 kb) were all below the 1st percentile of telomere length values observed in T cells from healthy agematched controls whereas telomere length of normal T-and B cells fell between the 1st and 99th percentile of the normal distribution. Leukemic T cells exhibited high levels of telomerase and were sensitive to the telomerase inhibitor BIBR1532 at doses that showed no effect on normal, unstimulated T cells. Targeting the short telomeres and telomerase activity in T-PLL seems an attractive strategy for the future treatment of this devastating disease.
Introduction
T-cell prolymphocytic leukemia (T-PLL) is a rare aggressive leukemia, poorly responsive to conventional chemotherapy, with a median survival of only 7.5 months in historic series. 1 This lymphoproliferative disease is characterized by specific clinical manifestation, morphology, immunophenotype and cytogenetics. 2 Most T-PLL cells exhibit a mature post-thymic CD2 þ , CD3 þ , CD7 þ , CD4 þ , CD8À immunophenotype but CD4 þ , CD8 þ and CD4À, CD8 þ cases are also seen. The genetic hallmark of T-PLL is the rearrangement of chromosome 14q32.1. 1 The leukemic cells are generally resistant to alkylating drugs and the most promising treatment results are currently achieved using chemo-immunotherapy protocols combining the anti-CD52 monoclonal antibody alemtuzumab with fludarabine, anthracyclines and alkylating agents. 1, 3 Telomeres are specialized structures at the end of eukaryotic chromosomes, which consist of 2-15 kb of noncoding tandem repeats of the sequence T 2 AG 3 4 and associated proteins 5 folded into a telomere loop structure. 6 Telomeres are required to maintain chromosomal integrity and prevent end-to-end fusions of chromosomes. When telomeric ends become too short, DNA damage signals from telomeres can induce apoptosis or a state of replicative senescence. 7, 8 Telomeres shorten with each round of cell division as a result of failure to completely replicate the 3 0 end of chromosomes 9, 10 as well as other causes. 11 The average telomere length in cells from most human tissues decreases with age in vivo and with culture in vitro. 12, 13 Disruption of control pathways like Rb or p53 allows cells to bypass senescence. Continued proliferation results in telomere attrition to the point where shortened telomeres no longer protect chromosome ends, leading to genomic instability facilitating the acquisition of additional mutations important for cancer progression, for example, by a process of fusion-bridge breakage that leads to the formation of complex nonreciprocal translocations. 14 The human telomerase complex, a ribonucleoprotein polymerase, is able to synthesize terminal T 2 AG 3 telomeric repeats de novo and thus extends or maintains telomeres. 5, 15 In contrast to germ line, stem or progenitor cells, most human somatic cells have only low or undetectable telomerase activity. Cells in numerous types of cancer and hematological malignancies upregulate telomerase to maintain telomeres in order to prevent replicative senescence or apoptosis. 16, 17 Therefore, telomerase seems an attractive target for the development of new cancer therapeutics. 18, 19 A variety of different classes of telomerase inhibitors, which block the catalytic activity of the enzyme or the access of telomerase to telomeres, have been tested. [20] [21] [22] This therapeutic approach was also shown with the use of dominant-negative mutant forms of hTERT, which lead to continuous telomere shortening and subsequent senescence or apoptosis. [23] [24] [25] [26] A novel nonpeptidic, non-nucleosidic inhibitor of the catalytic activity of telomerase is BIBR1532 (2-[(E)-3-naphtalen-2-yl-but-2-enoylamino]-benzoic acid). BIBR1532 inhibits telomerase activity, comprising the human telomerase reverse transcriptase and human telomerase RNA components, in a dose-dependent manner, with half-maximal inhibitory concentrations (IC 50 ) of 93 nM by interfering with the processivity of the enzyme. BIBR1532 is a noncompetitive inhibitor with a drugbinding site distinct from the binding sites for deoxyribonucleotides and the DNA primer. 27 One of the problems for the potential clinical use of telomerase inhibitors is that the effect is dependent on the telomere length reserve of the tumor cells. The response could be delayed until chromosomes run out of their telomeric repeats. Thus, the optimal situation for telomerase inhibition might be tumor cells with extremely short telomeres and high telomerase activity. Nevertheless, telomere length and levels of telomerase activity vary between different hematological neoplasias, which makes measurement of telomere length and telomerase activity a useful strategy to identify such situations. 28 Here, we can demonstrate that T-PLL cells have extremely short telomeres and high levels of telomerase activity. Furthermore, we show that inhibition of telomerase activity in T-PLL cells in vitro is cytotoxic, suggesting that telomerase inhibition should be further explored as a possible therapy for this devastating disease.
Materials and methods

Patients and samples
Ten T-PLL samples with cytogenetically detectable inv(14)(q11q32) or breakpoints in the TCL1 and TCRAD loci determined by fluorescence in situ hybridization (FISH) 29 as well as one T-PLL sample with clonal changes but without evidence of inv (14)/TCRAD-TCL1 fusion diagnosed according to the WHO criteria were selected for this study (Table 1) . Cells were obtained from peripheral venous blood samples after informed consent and according to institutional guidelines. Peripheral blood mononuclear cells (PBMCs) were separated by density centrifugation using Ficoll-Hypaque (Pharmacia, Freiburg, Germany). Genetic analyses were possible in all cases. Peripheral blood cells from age-matched healthy donors served as controls.
Cell culture, BIBR1532 and cytospin preparation
Cultures were initiated with 1 Â 10 6 cells ml À1 per well in 24-well tissue culture plates (Falcon, Becton Dickinson, Heidelberg, Germany) with fresh or thawed samples. T-PLL cells and normal T cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (Gibco, Karlsruhe, Germany) containing 10% pooled human AB serum (HS, Sigma, Munich, Germany), 100 U ml À1 penicillin per 100 mg ml À1 streptomycin (Gibco), 2 mM L-glutamine (Gibco), 1 mM sodium pyruvate MEM (Gibco), 1 Â MEM non essential amino acids (Gibco), 100 mg ml À1 kanamycin (Gibco), 0.05 mM 2-mercaptoethanol (Gibco) supplemented with 100 U ml À1 recombinant interleukin-2 (rIL-2; Proleukin, Chiron, Munich, Germany). T-PLL samples exhibited no active proliferation or expansion in short-term culture. BIBR1532 was synthesized by Boehringer Ingelheim (Biberach, Germany) and a stock solution of BIBR1532 at a concentration of 5 mM was prepared by dissolving the compound in 50% sterile dimethyl sulfoxide (DMSO) and RPMI 1640 medium (Gibco) and stored at À20 1C until use. Trypan blue exclusion was used to determine the number of viable and dead cells. Cytospin were prepared as described previously 30 and analyzed with a light microscope (Olympus, Hamburg, Germany) equipped with a digital camera (dhs MicroCam 3.3, dhs GmbH, Greifenstein-Beilstein, Germany). Digital images of cells observed with Â 100/1.35 oil objective lens were acquired using dhs Image Data Base software (dhs GmbH). In each treatment group 100 cells were analyzed at different time points for morphological signs of apoptosis and telomere dysfunction.
Telomere fluorescence in situ hybridization and flow cytometry
The average length of telomere repeats at chromosome ends in individual cells from the mononuclear cell fraction of T-PLL samples was measured by automated FISH and flow cytometry (flow-FISH) as described previously. 31 Briefly, mononuclear hTERT mRNA real-time PCR
Real-time PCR was performed with ABI Prism 7900HT Sequence Detector (Applied Biosystems, Foster City, CA, USA, http://www.appliedbiosystems.com) according to the manufacturer's instructions. PCR was carried out in a 20-ml reaction volume with a target-specific assay (Assays-on-demand Gene expression system; Applied Biosystems). For the quantification of each PCR result, we calculated the DC t value between the target gene and its endogenous control (GAPDH). DC t values from analysis in samples from individual T-PLL patients (n ¼ 7) were subtracted from the DC t values from normal Tcells (n ¼ 6). The 2 ÀDDCt value (relative quantity) was expressed as log fold change.
Statistical analysis
Microsoft Excel (Microsoft, Redmond, WA, USA) and Microcal Origin software (Origin Lab, Northamptom, MA, USA) were used for data analysis. Results are shown as means7s.d. of values obtained in independent experiments. The nonparametric Wilcoxon's signed-rank test was used to determine statistical significance (significance level Po0.05).
Results
Accumulation of T cells with extremely short telomeres in T-PLL
The characteristics of the 11 newly diagnosed or relapsed patients with sporadic T-PLL are shown in Table 1 . The average telomere length in subsets of peripheral blood leukocytes from the 11 patients was measured by automated multicolor flow-FISH. The leukemic T cells of all analyzed samples exhibited an extremely short telomere length of 1.5370.65 kb (mean7s.d., n ¼ 11) compared to 5.0370.71 kb for the normal T cells (P ¼ 0.008). The peaks of the telomere fluorescence from leukemic and normal T cells are well demonstrated in Figure 1a .
Practically, all of the measured telomere length values for the leukemic T cells were below the 1st percentile compared to telomere length values observed in T cells from healthy agematched controls (n ¼ 400), whereas the patients normal T cells fell between the 1st and 99th percentile of the normal distribution (Figure 1b) . For the corresponding B cells the average telomere length was 6.3770.71 kb (n ¼ 6) and all values were between the 1st and the 50th percentile of the normal distribution. For one patient with progressive disease (sample ID #101) we performed serial measurements of telomere length over a period of 18 months. The average telomere length in the T-cell clone remained stably short at 170.1 kb (normal T cell: 5.1 70.1 kb) with no additional telomere loss over time despite further expansion of the leukemic T cells (Figure 2) . In all analyzed samples, no cell doublets caused by fused or bridged chromosomes were observed as short telomeres can lead to telomere dysfunction with chromosome fusion and bridging.
Detection of T cells with high telomerase activity and expression of hTERT in T-PLL
We used the TRAP assay to quantify telomerase activity in cell lysates from T-PLL cells and normal T cells from healthy donors. Figure 3a shows that all of the analyzed T-PLL samples were positive for telomerase activity compared to no significant activity in normal unstimulated T cells. The relative levels of telomerase activity ranged from 8.0 to 90.0% of the positive control K562 (mean 52.9%727.0, n ¼ 7). For one patient (sample ID #102) we could also perform serial measurements of telomerase activity during the course of the disease. Here, the decrease of telomerase activity to normal levels correlated with the response to treatment (data not shown). As telomerase activity is regulated by the expression of hTERT, we analyzed hTERT expression by reverse transcription (RT)-PCR (Figure 3b) . The mean hTERT fold change (T-PLL/ND) was 10.8 (range 0.1-52.0). There was a strong correlation between telomerase activity and expression levels of hTERT (r ¼ 0.8, P ¼ 0.031, n ¼ 7).
Cytotoxic effect of BIBR1532 in T-PLL cells
The telomerase inhibitor BIBR1532 inhibits telomerase activity in human cancer cell lines, which leads to progressive shortening and subsequent dysfunction of telomeres. In order to explore the cytotoxic effect of BIBR1532 in T-PLL in vitro, we incubated T-PLL cells with BIBR1532 in short-term cultures. For these experiments we used concentrations of BIBR1532 between 10 and 100 mM. The viability of T-PLL cells treated with BIBR1532 decreased over time in culture (Figure 4a ) compared to no effect in normal, unstimulated T cells (Figure 4b ). After 10 days of short-term culture, the viability index (viable cells as percentage of untreated controls) was decreased in all analyzed samples in a dose-dependent manner ( Figure 5 Cytospins were prepared with BIBR1532 exposed T-PLL cells and analyzed under the microscope. The observed morphological changes like chromatin condensation and formation of apoptotic bodies were compatible with features of apoptosis ( Figure 6 ). Here we also found no morphological changes indicative of telomere dysfunction like cell doublets due to fused or bridged chromosomes.
Discussion
We found extremely short telomeres in leukemic T cells of the T-PLL samples compared to the residual corresponding normal T cells or to control samples. Most of the telomere length values of the leukemic T-PLL cells were below the 1st percentile of the normal range. As telomeres shorten with each cell division, the measured telomere length in T-PLL cells is compatible with an extensive proliferation of the leukemic T cell clone.
In most normal human cells, critically shortened telomeres activate DNA damage response pathways that induce cell cycle arrest, senescence or apoptosis. 34 For cultured and expanded CD4 þ T cells we found that this telomere checkpoint is reached at a telomere length of approximately 3.0 kb. 30 Malignant cells, however, manage to overcome those Telomeres and telomerase in T-PLL A Röth et al checkpoints so that further telomere shortening leads to dysfunctional telomeres with high genomic instability (telomere crisis). The observed extremely short telomeres in leukemic T cells of T-PLL samples, might in part explain the high frequency of cytogenetic aberrations seen in T-PLL samples. 35, 36 Dysfunctional telomeres are also associated with complex and largely unknown altered gene expression, which is a source of phenotypic variability and might drive the development of aggressive cancer cell clones. 5, 37 Analysis of telomerase activity revealed high levels of telomerase activity in samples from T-PLL patients almost comparable to the levels in the human leukemia cell line K562 used as positive control. As reported previously, telomerase activity seems to be necessary for the maintenance of critically short telomeres and enables further proliferation of the leukemic cells. 26 However, telomerase activity measured in cell extracts does not necessarily correlate to the telomere length. 38 Our longitudinal data over a period of 18 months with no significant changes in telomere length despite further cell proliferation for one T-PLL patient with progressive disease, would be compatible with the notion that telomerase is able to compensate telomere loss due to cell proliferation. Interestingly, leukemic T-PLL cells are able to survive and do not undergo apoptosis even with only 1 kb of telomeric repeats. Most likely the high levels of telomerase activity promote cell survival and growth, independently of net telomere elongation, for example, by capping telomeres, and therefore physically protecting telomere ends, as well as by a proposed anti-apoptotic function of hTERT. 30, 39, 40 In addition, we could not find any cell doublets caused by fused or bridged chromosomes as we demonstrated previously in hTERT-transduced normal CD4 þ T cells with high telomerase activity at a telomere length of about 3.0 kb. 30 Chromosome fusion and breakage might only be a phenomenon at the stage of telomere crisis, but once overcome and with the upregulation of telomerase it does not seem to appear or at least not in a significant frequency.
The high activity or upregulation of telomerase in malignant cells represents an attractive target for cancer therapeutics. 19 Telomerase inhibitor used as a single agent for cancer cells with longer telomeres will, however, progressively reduce telomere length, but there is an expected time delay or 'lag time' until cell death occurs. The ideal target cell for an anti-telomerase strategy appears, therefore, to be a cell with already short telomeres, which is dependent on telomerase for capping telomeres and further cell proliferation. 41 To test this hypothesis we incubated T-PLL cells with the telomerase inhibitor BIBR1532. This small molecule inhibitor has been shown to specifically inhibit the native and recombinant human telomerase comprising hTERT and hTR components by primarily interfering with the processivity of the enzyme. Treatment of carcinoma cells from lung, prostate, breast or fibrosarcoma with BIBR1532 lead to progressive telomere shortening followed by senescence or cell death. 27 High-dose BIBR1532 in the range of 30-100 mM which is higher than the published IC 50 value of 100 nM for the inhibition of the purified enzyme is reported to have also direct cytotoxic effects on cancer cells but not on normal hematopoetic stem cells. In this study the IC 50 value for this direct effect was found to be in the range of 50-60 mM. 27, 42 We found similar concentrations to be effective in T-PLL samples. In contrast, no significant effects were observed for normal unstimulated T cells. In addition to this cytotoxic effect telomerase inhibition has been described to also sensitize cancer cells to chemotherapeutic treatment, indicating the potential for telomerase inhibitors for combination therapies or for the treatment of drug resistant tumors. 43 Furthermore, both telomere length and telomerase activity might serve as attractive follow-up parameters to evaluate the treatment response for patients with T-PLL. Targeting telomerase and telomeres with telomerase inhibitor alone or in combination with other chemotherapeutic drugs for patients with T-PLL seems a promising and novel approach for the future treatment of this devastating disease. 
